What development phase is ATINVICITINIB in?

ATINVICITINIB is FDA-approved (marketed).

What are the side effects of ATINVICITINIB?

Common side effects include Vomiting or nausea, Otitis externa, Hematuria (without urinary tract infection), Anorexia, Bacterial skin infection, Diarrhea.

Last reviewed 2026-04-20 · How we verify

ATINVICITINIB

FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	ATINVICITINIB
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

Vomiting or nausea
Otitis externa
Hematuria (without urinary tract infection)
Anorexia
Bacterial skin infection
Diarrhea
Crystalluria
Lethargy
Urinary tract infection
Upset stomach, including flatulence, retching, and bloating
Neurological disorder (e.g., tremors, ataxia)
Ocular discharge

Serious adverse events

Leukopenia
Neutropenia
Eosinopenia
Monocytopenia
Lymphocytosis
Increased alanine aminotransferase (ALT)
Aspartate aminotransferase (AST) elevation
Symmetric dimethylarginine (SDMA) elevation
Hypercholesterolemia

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATINVICITINIB CI brief — competitive landscape report
ATINVICITINIB updates RSS · CI watch RSS